Evidence map›Paper›PMID 33241877›Full record

ArticleJournal of veterinary internal medicine2021

Effects of pimobendan on left atrial transport function in cats.

Samantha L Kochie, Karsten E Schober, Jaylyn Rhinehart, Randolph L Winter, John D Bonagura, Annie Showers, Vedat Yildez

Open access · goldAbstract readRandomized Controlled Trial, Veterinary
In one paragraph

Article in Journal of veterinary internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Use of pimobendan in cats: a practical evidence-based review.Journal of feline medicine and surgery · 2025
    Review
  3. Review
  4. Article
  5. Effects of pimobendan on left atrial transport function in cats.Journal of veterinary internal medicine · 2021
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Samantha L KochieDepartment of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-1299-2452
Karsten E SchoberDepartment of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-1286-0759
Jaylyn RhinehartDepartment of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0002-5549-3493
Randolph L WinterDepartment of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio, USA.
John D BonaguraDepartment of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio, USA.
Annie ShowersDepartment of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio, USA.
Vedat YildezCenter for Biostatistics, The Ohio State University, Columbus, Ohio, USA.
The Ohio State University · US

Funding

American College of Veterinary Internal Medicine GRT00049516College of Veterinary Medicine, Ohio State University 2017-19
6 · The paper itself

Abstract

backgroundArterial thromboembolism is a sequela of hypertrophic cardiomyopathy (HCM) in cats related to left atrial (LA) enlargement and dysfunction. HYPOTHESIS: Pimobendan improves LA transport function in cats. ANIMALS: Twenty-two client-owned cats with HCM and 11 healthy cats.

methodsProspective, double-blind, randomized, placebo-controlled clinical cohort study. Cats were randomized to receive either pimobendan (0.25 mg/kg PO q12h) or placebo for 4 to 7 days. Nineteen echocardiographic variables of LA size and function were evaluated. Statistical comparisons included t tests, analysis of variance, and multivariable analyses.

resultsPeak velocity of left auricular appendage flow (LAapp peak; mean ± SD, 0.85 ± 0.20 vs 0.71 ± 0.22 m/s; P = .01), maximum LA volume (P = .03), LA total emptying volume (P = .03), peak velocity of late diastolic transmitral flow (A peak velocity; 0.77 ± 0.12 vs 0.62 ± 0.17 m/s; P = .05), and A velocity time integral (A VTI; 3.05 ± 0.69 vs 3.37 ± 0.49; P = .05) were increased after pimobendan. Mean change after pimobendan was larger in cats with HCM compared to healthy cats for LA fractional shortening (2.1% vs -2.1%; P = .05), A VTI (0.58 vs 0.01 cm; P = .01), LAapp peak (0.20 vs 0.02 m/s; P = .02), LA kinetic energy (3.51 vs -0.10 kdynes-cm; P = .05), and LA ejection force (1.93 vs -0.07 kdynes; P = .01) in the multivariable model. The stronger effect of pimobendan in cats with HCM was independent of LA size. CONCLUSIONS AND CLINICAL IMPORTANCE: We identified positive, albeit minor, effects of pimobendan on LA function in cats with HCM. Whether or not treatment with pimobendan decreases the risk of cardiogenic embolism deserves further study.

Indexed as

Cardiomyopathy, HypertrophicCat DiseasesPyridazinesAnimalsAtrial Function, LeftCatsCohort StudiesHeart AtriaProspective StudiespimobendanPyridazinesarterial thromboembolismechocardiographyfelinehypertrophic cardiomyopathyVetmedin

Identifiers

PMID33241877
PMCPMC7848333
OpenAlexW3109555845

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.